Recon: FDA approves Otsuka subsidiary’s bile duct cancer drug Lytgobi; AstraZeneca buys LogicBio for $67M to grow genomics pipeline
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy